News Releases

2020-05/19
Minister of Health and Welfare led the delegation to visit United BioPharma for the COVID-19 vaccine development program
1
2020-04/27
United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
2
2020-03/25
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers
3
2020-03/24
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients
4
2020-03/19
San Miguel County orders residents to shelter in place before countywide coronavirus testing
5
2020-03/19
UBI 集團科研能量將攻堅新冠肺炎病毒帶來的人類大災難
6
2019-11/26
United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421
7
2019-11/08
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria
8
2019-10/07
PharmaBoardRoom interview of Dr. Chang Yi Wang, Chairperson and Chief Scientific Officer of United Biopharma (UBP)
9
2020-05/19
Minister of Health and Welfare led the delegation to visit United BioPharma for the COVID-19 vaccine development program
1
2020-04/27
United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
2
2020-03/25
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers
3
2020-03/24
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients
4
2020-03/19
San Miguel County orders residents to shelter in place before countywide coronavirus testing
5
2020-03/19
UBI 集團科研能量將攻堅新冠肺炎病毒帶來的人類大災難
6
2019-11/26
United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421
7
2019-11/08
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria
8
2019-10/07
PharmaBoardRoom interview of Dr. Chang Yi Wang, Chairperson and Chief Scientific Officer of United Biopharma (UBP)
9
UB-421 product received Gold Medal award for 2014 Pharmaceutical Technology Research and Development jointly given by Ministry of Economic Affairs and Minitry of Health, Taiwan 2014-12/15
Filed an IND submission of a phase I clinical trial for UB-621, an anti-HSV-gD antibody, with Taiwan Food and Drug Administration (TFDA) 2014-12/15
United BioPharma Licenses Innovative Antibody Drug 8D6 for Asthma and Allergy Treatment from Academia Sinica 2014-12/14
Completion of phase IIa clinical trial of UB-421, the anti-CD4 antibody for treatment in HIV treatment naïve patients 2014-11/15
United BioPharma was selected as the recipient by government’s Industrial Cooperation Program (ICP) to carry out the technology transfer of Single Use Disposal system in biological manufacturing from GE Healthcare 2014-09/15
anti-CD4 mAb drug candidate UB-421 won the Gold Medal Prize for Innovative Research and Development given by Taipei City government for 2014 Taipei Biotechnology Award 2014-09/15
United BioPharma was listed on the Taiwan Emerging Stock Market (Stock code : 6471) 2014-09/13
Establishment of UBP’s Clincial Research Center at the Hsinchu Biomedical Science Park 2014-05/15
United Biopharma held its opening ceremony at the 36th floor Auditorium of Taipei 101 building 2014-01/16
Establishment of a strategic alliance between UBP and Formosa Biomedical Technologies and the Chang-Gun Memorial Hospital of the Formosa Plastic Group 2013-10/30
United BioPharma, Inc. Copyright (c) 2020